Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin leads to higher bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Heparin‐induced thrombocytopaenia · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Success rate of replantation1 (analysed by participant) · patients undergoing digital replantation after traumatic amputation
It is very uncertain whether low molecular weight heparin changes success rate of replantation1 (analysed by participant, compared with unfractionated heparin (very low certainty).
1 finding from 1 review
Success rate of replantation1 (analysed by digit, · patients undergoing digital replantation after traumatic amputation
Low molecular weight heparin showed no clear difference in success rate of replantation1 (analysed by digit, compared with unfractionated heparin (low certainty).
1 finding from 1 review
Incidence of compromised microcirculation requiring invasive intervention (re‐exploration) (analysed by digit, · patients undergoing digital replantation after traumatic amputation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of compromised microcirculation requiring invasive intervention (incision) (analysed by participant/digit, · patients undergoing digital replantation after traumatic amputation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Microvascular insufficiency due to vessel occlusion ‐ arterial occlusion (analysed by digit, · patients undergoing digital replantation after traumatic amputation
It is very uncertain whether low molecular weight heparin changes microvascular insufficiency due to vessel occlusion ‐ arterial… compared with unfractionated heparin (very low certainty).
1 finding from 1 review
Microvascular insufficiency due to vessel occlusion ‐ venous occlusion (analysed by participant, · patients undergoing digital replantation after traumatic amputation
It is very uncertain whether low molecular weight heparin changes microvascular insufficiency due to vessel occlusion ‐ venous… compared with unfractionated heparin (very low certainty).
1 finding from 1 review
Complication and adverse reactions ‐ wound bleeding (analysed by participant, · patients undergoing digital replantation after traumatic amputation
Low molecular weight heparin showed no clear difference in complication and adverse reactions ‐ wound bleeding (analysed by… compared with unfractionated heparin (low certainty).
1 finding from 1 review
Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
PE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in PE at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
PE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in PE at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (7 days ‐ 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review